Der Verzehr von Soja und das Risiko von Brust- und Prostatakrebs

ZUSAMMENFASSUNG

Isoflavone werden traditionell als schwache Östrogene eingeordnet. Allerdings ist es schwierig, die Östrogenizität von Isoflavonen einzuschätzen. Als Lieferant von Isoflavonen kann Soja durch mehrere hormonabhängige und hormonunabhängige Mechanismen das Brustkrebs- und Prostatakrebsrisiko senken. Daher ist der regelmäßige Verzehr von Soja zu empfehlen.

SUMMARY

Soya consumption and the risk of breast and prostate cancer

Traditionally, isoflavones have been categorised as weak estrogens. Nonetheless it is not easy to estimate the estrogeneity of isoflavones. Soya, as a source of isoflavones can lead to the sinking of breast and prostate cancer risk by means of more hormone dependent and non-dependent mechanisms. Therefore the frequent consumption of Soya is recommended.

Soja - Isoflavone - östrogene Wirkung - Brustkrebs - Prostatakrebs - Sojaverzehr

Soya - breast and prostate cancer - isoflavones - estrogens

Literatur

• 01 Messina M, Barnes S. The role of soy products in reducing risk of cancer.  J Natl Cancer Inst.. 1991;  83 541-6
• 02 Murphy P A, Song T, Buseman G. et al. . Isoflavones in retail and institutional soy foods.  J Agric Food Chem.. 1999;  47 2697-704
• 03 Kuiper G G, Carlsson B, Grandien K. et al. . Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta.  Endocrinology.. 1997;  138 863-70
• 04 Kuiper G G, Lemmen J G, Carlsson B. et al. . Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta.  Endocrinology.. 1998;  139 4252-63
• 05 An J, Tzagarakis-Foster C, Scharschmidt T C, Lomri N, Leitman D C. Estrogen Receptor beta -Selective Transcriptional Activity and Recruitment of Coregulators by Phytoestrogens.  J Biol Chem.. 2001;  276 17808-14
• 06 Nestel P J, Pomeroy S, Kay S. et al. . Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women.  J Clin Endocrinol Metab.. 1999;  84 895-8
• 07 Nestel P J, Yamashita T, Sasahara T. et al. . Soy isoflavones improve systemic arterial compliance but not plasma lipids in menopausal and perimenopausal women.  Arterioscler Thromb Vasc Biol.. 1997;  17 3392-8
• 08 Duncan A M, Merz B E, Xu X, Nagel T C, Phipps W R, Kurzer M S. Soy isoflavones exert modest hormonal effects in premenopausal women.  J Clin Endocrinol Metab.. 1999;  84 192-7
• 09 Messina M J, Persky V, Setchell K D, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data.  Nutr Cancer.. 1994;  21 113-31
• 10 Kim H, Kim T G, Kim S. Mechanisms of action of the soy isoflavone genistein: emerging role for its effects via transforming growth factor beta signaling pathways.  Am J Clin Nutr.. 1998;  68 1418S-1425S
• 11 Patel R P, Boersma B J, Crawford J H. et al. . Antioxidant mechanisms of isoflavones in lipid systems: paradoxical effects of peroxyl radical scavenging.  Free Radic Biol Med.. 2001;  31 1570-81
• 12 Peterson G, Barnes S. Genistein inhibition of the growth of human breast cancer cells: independence from estrogen receptors and the multi-drug resistance gene.  Biochem Biophys Res Commun.. 1991;  179 661-7
• 13 Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation.  Prostate.. 1993;  22 335-45
• 14 Pisani P, Parkin D M, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990.  Int J Cancer.. 1999;  83 18-29
• 15 Barnes S, Grubbs C, Setchell K D, Carlson J. Soybeans inhibit mammary tumors in models of breast cancer.  Prog Clin Biol Res.. 1990;  347 239-53
• 16 Geynet C, Millet C, Truong H, Baulieu E E. Estrogens and antiestrogens.  Gynecol Invest.. 1972;  3 2-29
• 17 Morabia A, Costanza M C. International variability in ages at menarche, first livebirth, and menopause.  World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives [published erratum appears in Am J Epidemiol. 1999 Sep 1; 150(5): 546].  Am J Epidemiol.. 1998;  148 1195-205
• 18 Pike M C, Ross R K. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer.  Steroids.. 2000;  65 659-64
• 19 Folman Y, Pope G S. The interaction in the immature mouse of potent oestrogens with coumestrol, genistein and other utero-vaginotrophic compounds of low potency.  J Endocrinol.. 1966;  34 215-25
• 20 Foth C, Cline J M. Effects of mammalian and plant estrogens on mammary glands and uteri of macaques.  Am J Clin Nutr.. 1998;  68 1413S-1417S
• 21 Messina M J, Loprinzi C L. Soy for breast cancer survivors: a critical review of the literature.  J Nutr.. 2001;  131 3095S-108S
• 22 Gotoh T, Yamada K, Yin H, Ito A, Kataoka T, Dohi K. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary carcinogenesis by soy foods or biochanin A.  Jpn J Cancer Res.. 1998;  89 137-42
• 23 Hakkak R, Korourian S, Shelnutt S R, Lensing S, Ronis M J, Badger T M. Diets containing whey proteins or soy protein isolate protect against 7,12-dimethylbenz(a)anthracene-induced mammary tumors in female rats.  Cancer Epidemiol Biomarkers Prev.. 2000;  9 113-7
• 24 Zaizen Y, Higuchi Y, Matsuo N, Shirabe K, Tokuda H, Takeshita M. Antitumor effects of soybean hypocotyls and soybeans on the mammary tumor induction by N-methyl-n-nitrosourea in F344 rats.  Anticancer Res.. 2000;  20 1439-44
• 25 Gotoh T, Yamada K, Ito A, Yin H, Kataoka T, Dohi K. Chemoprevention of N-nitroso-N-methylurea-induced rat mammary cancer by miso and tamoxifen, alone and in combination.  Jpn J Cancer Res.. 1998;  89 487-95
• 26 Trock B, Butler W, Clarke R, Hilakivi-Clarke L. Meta-analysis of soy intake and breast cancer risk.  J Nutr.. (abstr)  2000;  130 690S-691S
• 27 Shimizu H, Ross R K, Bernstein L, Yatani R, Henderson B E, Mack T M. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles County.  Br J Cancer.. 1991;  63 963-6
• 28 Hemminki K, Li X. Cancer risks in second-generation immigrants to Sweden.  Int J Cancer.. 2002;  99 229-37
• 29 Hemminki K, Li X, Czene K. Cancer risks in first-generation immigrants to Sweden.  Int J Cancer.. 2002;  99 218-28
• 30 Tokunaga M, Land C E, Tokuoka S, Nishimori I, Soda M, Akiba S. Incidence of female breast cancer among atomic bomb survivors, 1950-1985.  Radiat Res.. 1994;  138 209-23
• 31 Lamartiniere C A, Zhao Y X, Fritz W A. Genistein: mammary cancer chemoprevention, in vivo mechanisms of action, potential for toxicity and bioavailability in rats.  J Women's Cancer.. 2000;  2 11-19
• 32 Badger T M, Ronis M J, Hakkak R, Rowlands J C, Korourian S. The health consequences of early soy consumption.  J Nutr.. 2002;  132 559S-65S
• 33 Shu X O, Jin F, Dai Q. et al. . Soyfood Intake during Adolescence and Subsequent Risk of Breast Cancer among Chinese Women.  Cancer Epidemiol Biomarkers Prev.. 2001;  10 483-8
• 34 Griffiths K. Estrogens and prostatic disease.  Prostate.. 2000;  45 87-100
• 35 Yatani R, Kusano I, Shiraishi T, Hayashi T, Stemmermann G N. Latent prostatic carcinoma: pathological and epidemiological aspects.  Jpn J Clin Oncol.. 1989;  19 319-26
• 36 Davis J N, Singh B, Bhuiyan M, Sarkar F H. Genistein-induced upregulation of p21WAF1, downregulation of cyclin B, and induction of apoptosis in prostate cancer cells.  Nutr Cancer.. 1998;  32 123-31
• 37 Santibanez J F, Navarro A, Martinez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines.  Anticancer Res.. 1997;  17 1199-204
• 38 Geller J, Sionit L, Partido C. et al. . Genistein inhibits the growth of human-patient BPH and prostate cancer in histoculture.  Prostate.. 1998;  34 75-9
• 39 Zhou J R, Gugger E T, Tanaka T, Guo Y, Blackburn G L, Clinton S K. Soybean phytochemicals inhibit the growth of transplantable human prostate carcinoma and tumor angiogenesis in mice.  J Nutr.. 1999;  129 1628-35
• 40 Dalu A, Haskell J F, Coward L, Lamartiniere C A. Genistein, a component of soy, inhibits the expression of the EGF and ErbB2/Neu receptors in the rat dorsolateral prostate.  Prostate.. 1998;  37 36-43
• 41 Mentor-Marcel R, Lamartiniere C A, Eltoum I E, Greenberg N M, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP).  Cancer Res.. 2001;  61 6777-82
• 42 Pollard M, Luckert P H. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats.  Nutr Cancer.. 1997;  28 41-5
• 43 Pollard M. Prevention of prostate-related cancers in Lobund-Wistar rats.  Prostate.. 1999;  39 305-9
• 44 Pollard M, Wolter W, Sun L. Prevention of induced prostate-related cancer by soy protein isolate/isoflavone-supplemented diet in Lobund-Wistar rats.  In Vivo.. 2000;  14 389-92
• 45 Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in lobund-wistar rats by a soy protein isolate/isoflavone diet.  Prostate.. 2000;  45 101-5
• 46 Severson R K, Nomura A M, Grove J S, Stemmermann G N. A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii.  Cancer Res.. 1989;  49 1857-60
• 47 Jacobsen B K, Knutsen S F, Fraser G E. Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States) [see comments].  Cancer Causes Control.. 1998;  9 553-7
• 48 Morton M S, Chan P S, Cheng C. et al. . Lignans and isoflavonoids in plasma and prostatic fluid in men: samples from Portugal, Hong Kong, and the United Kingdom.  Prostate.. 1997;  32 122-8
• 49 Urban D, Irwin W, Kirk M. et al. . The Effect of Isolated Soy Protein on Plasma Biomarkers in Elderly Men with Elevated Serum Prostate Specific Antigen.  J Urol.. 2001;  165 294-300
• 50 Hussain M, Sarkar F H, Djuric Z. et al. . Soy isoflavones in the treatment of prostate cancer.  J Nutr.. 2002;  132 575S-576S
• 51 U.S. Department of Agriculture .Modification of the Vegetable Protein Products Requirements for the National School Lunch Program, School Breakfast Program, Summer Food Service Program and Child and Adult Care Food Program. Federal Register 2000 7 CFR Parts 210, 215, 220, 225 and 226 12429 -12442
• 52 Kontessis P, Jones S, Dodds R. et al. . Renal, metabolic and hormonal responses to ingestion of animal and vegetable proteins.  Kidney Int.. 1990;  38 136-44
• 53 Kontessis P A, Bossinakou I, Sarika L. et al. . Renal, metabolic, and hormonal responses to proteins of different origin in normotensive, nonproteinuric type I diabetic patients.  Diabetes Care.. 1995;  18 1233
• 54 Breslau N A, Brinkley L, Hill K D, Pak C Y. Relationship of animal protein-rich diet to kidney stone formation and calcium metabolism.  J Clin Endocrinol Metab.. 1988;  66 140-6
• 55 Arjmandi B H, Smith B J. Soy isoflavones' osteoprotective role in postmenopausal women: mechanism of action.  J Nutr Biochem.. 2002;  13 130-137
• 56 Food and Drug Administration. . Food labeling, health claims, soy protein, and coronary heart disease.  Fed Reg.. 1999;  57 699-733
• 57 Walker H A, Dean T S, Sanders T A, Jackson G, Ritter J M, Chowienczyk P J. The phytoestrogen genistein produces acute nitric oxide-dependent dilation of human forearm vasculature with similar potency to 17b-Estradiol.  Circulation.. 2001;  103 258-262
• 58 Wiseman H, O'Reilly J D, Adlercreutz H. et al. . Isoflavone phytoestrogens consumed in soy decrease F(2)-isoprostane concentrations and increase resistance of low-density lipoprotein to oxidation in humans.  Am J Clin Nutr.. 2000;  72 395-400

Verfasser

Korrespondenzadresse